1610 related articles for article (PubMed ID: 33515320)
1. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis.
Velikova T; Georgiev T
Rheumatol Int; 2021 Mar; 41(3):509-518. PubMed ID: 33515320
[TBL] [Abstract][Full Text] [Related]
2. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccines: concerns beyond protective efficacy and safety.
Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
[TBL] [Abstract][Full Text] [Related]
4. Insights into new-onset autoimmune diseases after COVID-19 vaccination.
Guo M; Liu X; Chen X; Li Q
Autoimmun Rev; 2023 Jul; 22(7):103340. PubMed ID: 37075917
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
[TBL] [Abstract][Full Text] [Related]
6. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
Motamedi H; Ari MM; Dashtbin S; Fathollahi M; Hossainpour H; Alvandi A; Moradi J; Abiri R
Int Immunopharmacol; 2021 Jul; 96():107763. PubMed ID: 34162141
[TBL] [Abstract][Full Text] [Related]
7. The 2020 race towards SARS-CoV-2 specific vaccines.
Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
[TBL] [Abstract][Full Text] [Related]
8. Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines.
Fan Y; Geng Y; Wang Y; Deng X; Li G; Zhao J; Ji L; Zhang X; Song Z; Zhang H; Sun X; Gao D; Xie W; Huang H; Hao Y; Zhang Z
Ann Rheum Dis; 2022 Mar; 81(3):443-445. PubMed ID: 34824048
[No Abstract] [Full Text] [Related]
9. Are We Paving the Way to Dig Out of the "Pandemic Hole"? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization.
Tardiolo G; Brianti P; Sapienza D; dell'Utri P; Dio VD; Rao G; Calabrò RS
Med Sci (Basel); 2021 Jul; 9(3):. PubMed ID: 34449681
[TBL] [Abstract][Full Text] [Related]
10. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 vaccine candidates in rapid development.
Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
[TBL] [Abstract][Full Text] [Related]
12. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
14. [SARS-CoV-2 vaccines].
Benfield TL; Helweg-Larsen J
Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
[TBL] [Abstract][Full Text] [Related]
15. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. Adverse Cardiovascular Effects of COVID-19 Vaccination: A Systematic Review.
Huang JH; Ju KS; Liao TW; Lin YK; Yeh JS; Chen YJ
Cardiol Rev; 2024 Jul-Aug 01; 32(4):314-319. PubMed ID: 38848534
[TBL] [Abstract][Full Text] [Related]
18. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
19. New-onset autoimmune phenomena post-COVID-19 vaccination.
Chen Y; Xu Z; Wang P; Li XM; Shuai ZW; Ye DQ; Pan HF
Immunology; 2022 Apr; 165(4):386-401. PubMed ID: 34957554
[TBL] [Abstract][Full Text] [Related]
20. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena.
Chavda VP; Bezbaruah R; Athalye M; Parikh PK; Chhipa AS; Patel S; Apostolopoulos V
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
